Please assess the completion status of the following clinical trial:

Trial Title: A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-Participants and Target Disease Characteristics- -~* Confirmed disease progression by RECIST 1.1 criteria on nivolumab maintenance after induction with ipilimumab and nivolumab~* Progress of maintenance treatment of nivolumab by RECIST. Pathology report must be submitted for embedded tissue block or tumor tissue.~Age and Reproduction Sexually active males with WOCBP must agree to instructions for contraception and fetal protection.~WOCBP need to use contraception throughout the study and for 5 months post treatment.~Exclusion Criteria autoimmune disease statement~* Active central nervous system metastases~* Participants with an active autoimmune disease, diabetes mellitus, skin disorders, hyperthyroidism requiring hormone treatments are permitted to enroll.~* Any major surgery 28 days before 1st treatment Concomitant Therapy~* participants that have received a live vaccine within 30 days of treatment.~* use of investigational agent or device with in 28 days before first dosage study treatment.~Physical and Laboratory Test Findings Allergies and Adverse Drug Reaction Age and Reproduction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab + Ipilimumab (combination) (Type: EXPERIMENTAL): Nivolumab + Ipilimumab (combination) Q3W for 4 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).